Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aprepitant + palonosetron
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Aprepitant + palonosetron is a combination regimen used to prevent chemotherapy-induced nausea and vomiting (CINV). Aprepitant is a neurokinin-1 (NK-1) receptor antagonist that blocks the action of substance P in the brain, thereby preventing both acute and delayed phases of CINV. Palonosetron is a serotonin 5-HT3 receptor antagonist that blocks serotonin receptors in the gastrointestinal tract and central nervous system, primarily preventing acute CINV. This combination may be administered alongside dexamethasone for optimal antiemetic efficacy. The regimen leverages the complementary mechanisms of both drugs to provide broad-spectrum protection against nausea and vomiting associated with cancer chemotherapy[6][7].
- Brand names
- Emend + Aloxi
- Other names
- aprepitant and palonosetronaprepitant with palonosetron
02
Targets
TACR1 (Neurokinin‑1 Receptor)HTR3A (5-hydroxytryptamine receptor 3A)
Beyond the preview
Go deeper on aprepitant + palonosetron.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aprepitant + palonosetron.